circSLC25A13 acts as a ceRNA to regulate AML progression via miR‐616‐3p/ADCY2 axis
Molecular Carcinogenesis · 2023
DOI: 10.1002/mc.23598 ↗At a glance
Journal article in Molecular Carcinogenesis, 2023. Written by Wenwen Wei and 16 co-authors. Institution: Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China. Major MEDLINE topics: Leukemia, Myeloid, Acute, MicroRNAs. Cited 6 times so far (Crossref); 24 references. Funded by: National Natural Science Foundation of China.
Abstract (original language)
Circular RNAs (circRNAs), a type of endogenous noncoding RNA (ncRNA), exert vital roles in leukemia progression and are promising prognostic factors. Here, we report a novel circRNA, circSLC25A13 (hsa_circ_0081188), which was increased in acute myeloid leukemia (AML) patients with poor overall survival (OS) comparing to patients with good prognosis. Knockdown of circSLC25A13 in AML cells inhibited proliferation and increased cell apoptosis in vitro and in vivo. Enhanced circSLC25A13 expression promoted the survival of AML cells. Mechanistically, circSLC25A13 played as a microRNA sponge of miR‐616‐3p, which inhibited the expression of adenylate cyclase 2 (ADCY2). Downregulation of miR‐616‐3p and overexpression of ADCY2 partially rescued circSLC25A13 deficient induced cell growth arrest. In summary, through competitive absorption of miR‐616‐3p and thereby upregulating ADCY2 expression, circSLC25A13 promoted AML progression. Moreover, circSLC25A13 may represent a potential novel biomarker for the prognosis of AML and offer a potential therapeutic target for AML treatment.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
- Zhejiang Provincial Key Laboratory of Hematologic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.
- Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, Zhejiang, People's Republic of China.
- Zhejiang University Cancer Center, Hangzhou, Zhejiang, People's Republic of China.
- Department of Laboratorial Medicine, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
- Jinan Microecological Biomedicine Shandong Laboratory, Jinan, Shandong, People's Republic of China.
ORCID profiles: Jie Jin
Funding
- National Natural Science Foundation of China
Cite
APA
Wei, W., Pan, J., Wang, J., Mao, S., Qian, Y., Lin, X., Ling, Q., Ye, W., Zhou, Y., Zhao, Y., Huang, J., Huang, X., Ma, Z., Wang, H., Li, C., Sun, J., & Jin, J. (2023). circSLC25A13 acts as a ceRNA to regulate AML progression via miR‐616‐3p/ADCY2 axis. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23598
Vancouver
Wei W, Pan J, Wang J, Mao S, Qian Y, Lin X, et al. circSLC25A13 acts as a ceRNA to regulate AML progression via miR‐616‐3p/ADCY2 axis. Molecular Carcinogenesis. 2023. doi:10.1002/mc.23598
BibTeX
@article{Wei2023,
author = {Wei, Wenwen and Pan, Jiajia and Wang, Jinghan and Mao, Shihui and Qian, Yu and Lin, Xiangjie and Ling, Qing and Ye, Wenle and Zhou, Yutong and Zhao, Yanchun and Huang, Jiansong and Huang, Xin and Ma, Zhixin and Wang, Huanping and Li, Chenying and Sun, Jie and Jin, Jie},
title = {circSLC25A13 acts as a ceRNA to regulate AML progression via miR‐616‐3p/ADCY2 axis},
journal = {Molecular Carcinogenesis},
year = {2023},
doi = {10.1002/mc.23598}
}
EUVIMED